The involvement of ABCG2 in irinotecan resistance was corroborated in clinical samples from colon cancer patients demonstrating increased levels of the ABCG2 mRNA in hepatic metastases after irinotecan-based chemotherapy in comparison with irinotecan-naive metastases. Here, ABCG2 is linked to colonic neoplasm.